JNJ

233.01

+1.03%↑

UNH

284.01

-0.6%↓

TMO

568.43

-2.07%↓

ABT

108.96

-0.46%↓

ISRG

478.71

-3.54%↓

JNJ

233.01

+1.03%↑

UNH

284.01

-0.6%↓

TMO

568.43

-2.07%↓

ABT

108.96

-0.46%↓

ISRG

478.71

-3.54%↓

JNJ

233.01

+1.03%↑

UNH

284.01

-0.6%↓

TMO

568.43

-2.07%↓

ABT

108.96

-0.46%↓

ISRG

478.71

-3.54%↓

JNJ

233.01

+1.03%↑

UNH

284.01

-0.6%↓

TMO

568.43

-2.07%↓

ABT

108.96

-0.46%↓

ISRG

478.71

-3.54%↓

JNJ

233.01

+1.03%↑

UNH

284.01

-0.6%↓

TMO

568.43

-2.07%↓

ABT

108.96

-0.46%↓

ISRG

478.71

-3.54%↓

Kodu・Aktsiate loetelu・Actinium Pharmaceuticals Inc

Actinium Pharmaceuticals Inc

Suletud

1.19 -1.65

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.17

Max

1.22

Põhinäitajad
By Trading Economics
Sissetulek	1.7M -5.1M
Müük	90K 90K
Kasumimarginaal	-5,701.111
Töötajad	25
EBITDA	2.6M -4.9M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+391.8% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	27. märts 2026

Turustatistika
By TradingEconomics
Turukapital	-1.9M 40M
Eelmine avamishind	2.84
Eelmine sulgemishind	1.19

Actinium Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

3. veebr 2026, 23:11 UTC

Suurimad hinnamuutused turgudel

Omandamised, ülevõtmised, äriostud

Silicon Laboratories Shares Up On Report of $7 Billion Texas Instruments Acquisition Deal

3. veebr 2026, 23:50 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

3. veebr 2026, 23:50 UTC

Market Talk

Nikkei May Decline After Hitting All-Time High -- Market Talk

3. veebr 2026, 23:42 UTC

Market Talk

Gold Edges Lower on Possible Technical Correction -- Market Talk

3. veebr 2026, 23:41 UTC

Omandamised, ülevõtmised, äriostud

KKR Makes AI Play With $10.9B Asia Data-Center Deal

3. veebr 2026, 23:38 UTC

Tulu

AMD Sales Climb on Help From Data-Center Business -- Update

3. veebr 2026, 23:29 UTC

Omandamised, ülevõtmised, äriostud

KKR-Consortium Deal in STT GDC Is One of the Largest Digital-Infrastructure Transactions in Southeast Asia

3. veebr 2026, 23:27 UTC

Omandamised, ülevõtmised, äriostud

Netflix, Warner Defend Proposed Deal in Senate Hearing -- WSJ

3. veebr 2026, 23:25 UTC

Omandamised, ülevõtmised, äriostud

KKR-Consortium Expects Deal to Close by Early 2H of 2026

3. veebr 2026, 23:23 UTC

Omandamised, ülevõtmised, äriostud

KKR Consortium With Singtel to Own 75% and 25% Stake in ST Telemedia Global Data Centres

3. veebr 2026, 23:22 UTC

Omandamised, ülevõtmised, äriostud

KKR-Led Consortium to Buy Singapore-Based Global Data-Center Provider Valued at S$13.8B

3. veebr 2026, 23:19 UTC

Market Talk

Australia Gold Miners Tipped to Rally Higher -- Market Talk

3. veebr 2026, 23:19 UTC

Market Talk

Global Equities Roundup: Market Talk

3. veebr 2026, 22:56 UTC

Suurimad hinnamuutused turgudel

Omandamised, ülevõtmised, äriostud

Silicon Laboratories Shares Up On Report of $7B Texas Instruments Acquisition Deal

3. veebr 2026, 22:40 UTC

Tulu

Amdocs Extends Collaboration With T-Mobile

3. veebr 2026, 22:39 UTC

Tulu

Amdocs 1Q Adj EPS $1.81

3. veebr 2026, 22:39 UTC

Tulu

Amdocs 1Q Rev $1.16B

3. veebr 2026, 22:39 UTC

Tulu

Amdocs 1Q EPS $1.45 >

3. veebr 2026, 22:38 UTC

Tulu

Amdocs: Shimie Hortig to Succeed Shuky Sheffer as President and CEO, Effective March 31

3. veebr 2026, 22:30 UTC

Omandamised, ülevõtmised, äriostud

Bob Iger's Second Time as CEO Wasn't Great for the Stock. He Still Leaves Behind A Strong Legacy. -- Barrons.com

3. veebr 2026, 22:22 UTC

Omandamised, ülevõtmised, äriostud

Texas Instruments Nearing $7B Deal for Silicon Laboratories, Sources Tell FT

3. veebr 2026, 22:14 UTC

Tulu

AMD Expects to Scale AI Business to Tens of Billions in Annual Sales in 2027, CEO Says

3. veebr 2026, 22:13 UTC

Tulu

AMD Expects Data-Center Unit Sales to Jump More Than 60% a Year Over Next Three to Five Years, CEO Says

3. veebr 2026, 22:12 UTC

Tulu

AMD in Talks With Several Companies About At-Scale, Multi-Year Chip Deployments, CEO Says

3. veebr 2026, 22:10 UTC

Tulu

AMD CEO: Eight of 10 Biggest AI Companies Use Instinct Chip to Power Production Workloads

3. veebr 2026, 22:10 UTC

Tulu

Blackstone Stock, Alternative Managers, BDCs Dive as Software Woes Infect Private Credit -- Barrons.com

3. veebr 2026, 22:10 UTC

Market Talk

Key Drivers Underpinning Shaw's Bullish View of Gold Intact -- Market Talk

3. veebr 2026, 22:10 UTC

Tulu

AMD CEO: Enterprises Are Modernizing Data Centers to Have Compute Needed for New AI Workflows

3. veebr 2026, 22:09 UTC

Tulu

AMD CEO: Hyperscalers Expanding Infrastructure to Meet Growing Cloud-Services Demand in AI

3. veebr 2026, 22:09 UTC

Tulu

AMD CEO: Demand Accelerated Across Data Center, Gaming and PC

Võrdlus sarnastega

Hinnamuutus

Actinium Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

391.8% tõus

12 kuu keskmine prognoos

Keskmine 6 USD 391.8%

Kõrge 9 USD

Madal 4 USD

Põhineb 3 Wall Streeti analüütiku instrumendi Actinium Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

3 ratings

Osta

Hoia

Müü

Põhineb 3 analüütiku instrumendi Actinium Pharmaceuticals Inc aktsia reitingul - viimase 3 kuu andmed.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Actinium Pharmaceuticals Inc

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company's research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.